Does deamidation of survodutide at 25 °C show up as a loss of content or of purity?

For reference: deamidation · survodutide · 25 °C.

I understand the observation; what I do not understand is the mechanism behind it.

I have read the two review articles that come up first and both assert this without a citation to a primary source.

What is actually going on here, physically?

At 25 °C it can show up as either, and which one depends entirely on whether the product still elutes under the main peak. Purity is a ratio of areas, so a degradant only costs purity if the method resolves it. Content is a mass against a standard, so a degradant costs content whenever the parent is consumed — resolved or not. Asn and Gln lose the amide through a succinimide intermediate, so the product is one dalton heavier and usually resolves as a shoulder on the main peak rather than as a peak of its own. That is why the two measurements are not interchangeable and why an unchanged purity figure after an excursion to 25 °C is weak evidence: the method may simply be integrating the degradant along with the parent and reporting the sum as one peak.

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Degradation pathway by condition

On the detail: freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

Cold, dry, dark, still. Those four words cover most of the mitigation.

edited 2 Aug 2025 by n_takahashi — reworded for clarity after a comment

The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

Answering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

At dilute concentrations, suspect adsorption before you suspect chemistry.

The part that matters: asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Sequence decides which pathways are even available. Check the residues.